Mortality among HIV-exposed infants: The first and final frontier

Clinical Infectious Diseases

Volumn 50, Issue 3, 2010, Pages 445-447

  Shapiro, Roger L ^a,b   Lockman, Shahin ^b,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

BREAST FEEDING; CD4 LYMPHOCYTE COUNT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT FEEDING; INFANT MORTALITY; INFECTION RISK; NOTE; PRIORITY JOURNAL; RISK FACTOR; TRANSACTIVATION;

AFRICA SOUTH OF THE SAHARA; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALE; MORTALITY; SURVIVAL ANALYSIS; WEANING;

EID: 75749091138     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/649887     Document Type: Note

References (21)

1. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-I transmission. N Engl J Med 2008; 359:119-129.
2. Bedri A, Gudetta B, Isehak A, et al. Extendeddose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet 2008; 372:300-313.
3. Chasela C, Hudgens M, Jamieson D, et al. Both maternal HAART and daily infant nevirapine (NVP) are effective in reducing HIV1 transmission during breastfeeding in a randomized trial in Malawi: 28 week results of the Breastfeeding, Antiretroviral and Nutrition. (BAN) Study. In: Program and abstracts of the Fifth International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention, Cape Town, South Africa, 19-22 July 2009. Abstract WELBC103.
4. Shapiro RL, Hughes M, Ogwu A, et al. A randomized trial comparing highly active antiretroviral therapy regimens for virologie efficacy and the prevention of mother-to-child HIV transmission, among breastfeeding women in Botswana (The Mma Bana Study). In: Program and abstracts of the Fifth International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention, Cape Town, South Africa, 19-22 July 2009. Abstract WELBB101.
5. Palombi L, Marazzi MC, Voetberg A, Magid NA. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV. AIDS 2007; 21(Suppl 4):S65-S71. (Pubitemid 47051751)
6. de Vincenzi I; Kesho Bora Study Group. Triple-antiretroviral (ARV) prophylaxis during pregnancy and breastfeeding compared to short-ARV prophylaxis to prevent mother-tochild transmission, of HIV-1 (MTCT): the Kesho Bora randomized controlled clinical trial in five sites in Burkina Faso, Kenya, and South Africa. In: Program and abstracts of the Fifth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 19-22 July 2009. Abstract LBPECO1.
7. Arendt V, Ndimubanzi P, Vyankandondera J, et al. AMATA study: effectiveness of antiretroviral therapy in breastfeeding mothers to prevent post-natal vertical transmission in Rwanda. In: Program and abstracts of the Fourth International AIDS Society Conference on HIV Treatment and Pathogenesis, Sydney, Australia, 22-25 July 2007. Abstract TuAX102.
8. Kilewo C, Karlsson K, Ngarina M., et al. Prevention of mother to child transmission of HIV-I through breastfeeding by treating mothers prophylactically with triple antiretroviral therapy in Dar es Salaam, Tanzania- the MITRA Plus study. In: Program and abstracts of the Fourth International AIDS Society Conference on HIV Treatment and Pathogenesis, Sydney, Australia, 22-25 July 2007. Abstract TuAX101.
9. World Health Organization. The World Health Report 2005: make every mother and child count. Geneva, Switzerland: World Health Organization Press, 2005.
10. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected and uninfected infants born to HIVinfected mothers in Africa: a pooled analysis. Lancet 2004; 364:1236-1243. (Pubitemid 39311344)
11. Kuhn L, Aldrovandi GM, Sinkala M, et al. Effects of early, abrupt weaning for HIV-free survival of children in Zambia. N Engl J Med 2008; 359:130-141. (Pubitemid 351962036)
12. Thior I, Lockman S, Smeaton LM, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA 2006; 296:794-805.
13. Marinda E, Humphrey JH, Iliff PJ, et al. Child mortality according to maternal and infant HIV status in Zimbabwe. Pediatr Infect Dis J 2007; 26:519-526.
14. Brahmbhatt H, Kigozi G, Wabwire-Mangen F, et al. Mortality in HIV-infected and uninfected children of HIV-infected and uninfected mothers in.rural Uganda. J Acquir Immune Defic Syndr 2006; 41:504-508. (Pubitemid 43756168)
15. Shapiro RL, Lockman S, Kim S, et al. Infant morbidity, mortality, and breast milk immunologic profiles among breast-feeding HIV-infected and HIV-uninfected women in Botswana. J Infect Dis 2007; 196:562-569. (Pubitemid 47206103)
16. Kuhn L, Sinkala M, Semrau K, et al. Elevations in mortality associated with weaning persist into the second year of lite among uninfected children born to HIV-infected mothers. Clin Infect Dis 2010; 50:437-444 (in this issue).
17. Thea DM, St. Louis ME, Atido U. A prospective study of diarrhea and HIV-1 infection among 429 Zairian infants. N Engl J Med 1993; 329:1696-1702. (Pubitemid 23346920)
18. Harris JR, Greene SK, Thomas TK, et al. Effect of a point-of-use water treatment and safe water storage intervention on diarrhea in infants of HIV-infected mothers. J Infect Dis 2009; 200: 1186-1193.
19. Mehta S, Hunter DJ, Mugusi FM, et al. Perinatal outcomes, including mother-to-child transmission of HIV, and child mortality and their association with maternal vitamin D status in Tanzania. J Infect Dis 2009; 200: 1022-1030.
20. Walter J, Mwiya M, Scott N, et al. Reduction in preterm delivery and neonatal mortality after the introduction of antenatal cotrimoxazole prophylaxis among HIV-infected women with low CD4 cell counts. J Infect Dis 2006; 194:1510-1518. (Pubitemid 44851892)
21. Chintu C, Bhat GJ, Walker AS, et al. Co-trimoxazole as prophylaxis against opportunistic infections in. HIV-infected Zambian children (CHAP): a double-blind randomised placebocontrolled trial. Lancet 2004; 364:1865-1871.